Literature DB >> 27499321

Primary malignant fibrous histiocytoma of long bones: long-term follow-up.

Bülent Özkurt1, Kerem Başarır, Yusuf H Yıldız, Mahmut Kalem, Yener Sağlık.   

Abstract

OBJECTIVES: This study aims to evaluate patients diagnosed with malignant fibrous histiocytoma and investigate the possible prognostic factors associated with duration of survival. PATIENTS AND METHODS: The study, which was conducted between May 1994 and September 2013, included 14 patients diagnosed as malignant fibrous histiocytoma (12 males, 2 females; median age 48 years; range 17 to 64 years). We evaluated patients' demographic features, location of the pathology, histological findings, surgical margins, and treatment modalities and investigated the effects of these parameters on survival.
RESULTS: Femur was the most frequently involved bone, followed by tibia and humerus. The median follow-up duration of the patients was 129 months. We performed limb salvage surgeries in 13 patients and amputation in one patient. Surgical margins were marginal in three patients and postoperative radiotherapy was performed for local control of the disease. Although there was no local recurrence in these patients, distant metastasis developed in two patients, indicating the importance of surgical margin as a significant factor on survival. Five-year survival rate was 81.9% in patients with wide surgical margins and 33.3% in patients with marginal margins.
CONCLUSION: Surgical excision with wide margins and adjuvant chemotherapy provided adequate control of the disease and longer survival. The only prognostic factor statistically significantly associated with duration of survival was surgical margins. Neoadjuvant chemotherapy may be used when there is a suspicion of not obtaining adequately wide surgical margin perioperatively due to close association with neurovascular structures.

Entities:  

Mesh:

Year:  2016        PMID: 27499321     DOI: 10.5606/ehc.2016.20

Source DB:  PubMed          Journal:  Eklem Hastalik Cerrahisi


  8 in total

1.  Undifferentiated pleomorphic sarcoma of the extremity and trunk: a retrospective cohort study of 166 cases in a large institution.

Authors:  Shuguang Zhang; Xinxin Zhang; Zhenguo Zhao; Libin Xu; Songfeng Xu; Ting Liu; Shengji Yu
Journal:  Transl Cancer Res       Date:  2022-04       Impact factor: 0.496

2.  Carbon ion radiotherapy for unresectable primary undifferentiated pleomorphic sarcoma of the 11th thoracic spine: a case report.

Authors:  Fuminori Murase; Hiroatsu Nakashima; Kenyu Ito; Yusuke Demizu; Tetsuro Takatsu
Journal:  J Rural Med       Date:  2022-07-01

3.  Pleomorphic Sarcoma in a Patient with Osteopetrosis.

Authors:  Kevin McGill; Daria Motamedi; Nima Azimi; Andrew Horvai; Richard O'Donnell
Journal:  J Radiol Case Rep       Date:  2020-07-31

4.  The Significance of a "Close" Margin in Extremity Sarcoma: A Systematic Review.

Authors:  Ike Hasley; Yubo Gao; Amy E Blevins; Benjamin J Miller
Journal:  Iowa Orthop J       Date:  2018

5.  [Solitary locoregional metastasis of an undifferentiated pleomorphic sarcoma in the M. quadratus femoris].

Authors:  Mohamad Bdeir; Nikolaos Vassos; Ali Darwich; Cleo-Aron Weis; Sascha Gravius; Eva Renker
Journal:  Orthopade       Date:  2021-03-17       Impact factor: 1.087

6.  Malignant fibrous histiocytoma in the right portion of the mandible with metastasis in pancreas.

Authors:  Javier Biurrun Chamale; Marco Bruno; Facundo Mandojana; Llugdar José; Lucas Armando; Doniquian Alejandro
Journal:  Int J Surg Case Rep       Date:  2017-10-12

7.  Rare pancreatic metastasis of undifferentiated pleomorphic sarcoma originating from the pelvis: A case report.

Authors:  Manato Ohsawa; Yoshihiro Mikuriya; Koji Ohta; Minoru Tanada; Noriaki Yamamoto; Norihiro Teramoto; Masahiro Kiyono; Shinsuke Sugihara
Journal:  Int J Surg Case Rep       Date:  2020-02-21

8.  Malignant fibrous neoplasms of long bones: analysis of the surveillance, epidemiology, and end results database from 1973 to 2015.

Authors:  Yiting Huang; Jianqiao Hong; Jiahong Meng; Haobo Wu; Mingmin Shi; Shigui Yan; Wei Wang
Journal:  BMC Musculoskelet Disord       Date:  2020-01-22       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.